Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Estimated effect of evidence from human genetic studies on the probability of advancing in clinical development. A: Partitioning Pharmaprojects, OMIM, and GWAS Catalog into training data available to Nelson et al. 2015 and validation sets. We use validation set Pipeline Progression, consisting of target-indication pairs assigned a clinical phase in 2013, to determine whether gene target-indication pairs with genetic evidence were more likely to advance to the next pipeline phase from 2013-2018. Pharmaprojects target-indication pairs absent from or assigned an unknown clinical phase in the Nelson et al. dataset form the New Pipeline replication set. Pharmaprojects target-indication pairs approved prior to 2013 or with unknown phase in our dataset are not part of any replication set. B: Our estimates of the effect of genetic evidence on gene target-indication pair progression compared to values reported by Nelson et al. 2015 [3] in validation sets New Pipeline (drugs and indications > 2013, 2013 inactive drugs) New Genetic (only new genetic information > 2013) Pipeline Progression, and in the full updated dataset (Full Data). Estimates falling close to the identity line (shown in black) are consistent between the two analyses.](https://figures.cochat.ai/paper-figures/fbfe5599a9364dd7aab42f07a9e12b6a/are-drug-targets-with-genetic-support-twice-as-likely-to-be-approved-revised-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is supported by drug candidates with genetically supported targets being significantly more likely to progress through phased clinical trials (9, 10).”
From Identification of human gene research articles with wrongly identified nucleotide sequences (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,697
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Watanabe, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1004.2316 · Cited by 2,226
Research works printed but not linked: 1
- J MacArthur, 2016, The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Research, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
Cited by
Items 501–600 of 648
Gill, D. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.5.pr1
The potential of Senicapoc, a KCNN4 inhibitor, for the prevention and treatment of breast cancerPreprint
Xiao, C., Miranda, M. S., Shi, W., Beesley, J., Saunus, J. M., Civitarese, A., Black, D. M., Ruppert, M., Pereira, M., Jackson, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.25.538345
Zhao, J., Liu, F., Worth, C., Simone, D., Penkava, F., Shi, H., Li, J., Lama, S., Fang, H., Lee, J. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.10.544264
Voda, A.-I., & Jostins-Dean, L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.13.544716
The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics
Buyukkurt, A., & Harroud, A. (2023) · Neurology · doi:10.1212/wnl.0000000000207773
Membranous Nephropathy: Muti-omics Mendelian randomization and colocalization analysisPreprint
Su, Z., Liu, W., Yin, Z., Wu, D., Cheng, Y. S., & Wan, Q. (2023) · medRxiv · doi:10.1101/2023.11.21.23298831
Precision medicine and drug safety
Handler, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00037-x
Bioinformatics for Medicinal Chemistry
Manners, E. J., O’Donovan, C., & Martin, M. J. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00485
Zhang, C., Zhang, F., Min, S., Liu, D., Qin, X., Wang, Z., & Zhang, M. (2024) · Research Square · doi:10.21203/rs.3.rs-3926579/v1
Additional file 2 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622549
Additional file 7 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622564
Gu, X., Dou, M., Su, W., Jiang, Z., Duan, Q., Cao, B., & Chen, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22599619
Khan, Z., Jung, M., Crow, M., Mohindra, R., Maiya, V., Kaminker, J. S., Hackos, D. H., Chandler, G. S., McCarthy, M. I., & Bhangale, T. (2023) · Figshare · doi:10.6084/m9.figshare.23558039
Khan, Z., Jung, M., Crow, M., Mohindra, R., Maiya, V., Kaminker, J. S., Hackos, D. H., Chandler, G. S., McCarthy, M. I., & Bhangale, T. (2023) · Figshare · doi:10.6084/m9.figshare.23558036
Additional file 5 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622558
Additional file 3 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622552
Khan, Z., Jung, M., Crow, M., Mohindra, R., Maiya, V., Kaminker, J. S., Hackos, D. H., Chandler, G. S., McCarthy, M. I., & Bhangale, T. (2023) · Figshare · doi:10.6084/m9.figshare.23558045
Additional file 6 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622561
Additional file 8 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622567
Additional file 4 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622555
Omics Sciences in Drug Discovery, Safety, and Pharmacokinetics
Giovanni, T., Giannese, F., & Lazarević, D. (2024) · Springer eBooks · doi:10.1007/978-3-030-73317-9_131-1
Choi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B., & Lee, J. (2024) · eLife · doi:10.7554/elife.89782.2.sa4
Minimizing biological risk for novel inhibitory drug targets: One knockout is all you needPreprint
Dimitriev, A., Postovit, L.-M. M., Simpson, A. L., & Wong, G. K. (2024) · medRxiv · doi:10.1101/2024.06.19.24309116
Stopped clinical trials give evidence for the value of genetics
King, E. A. (2024) · Nature Genetics · doi:10.1038/s41588-024-01834-3
Self-citationTrends in drug development for rare and intractable diseases based on the KEGG NETWORK
Tanabe, M., Hirata, M., & Sakate, R. (2024) · NAR Molecular Medicine · doi:10.1093/narmme/ugae009
Gene-statin interaction study identifies 9 loci that moderate statin effectiveness in blood lipidsPreprint
Verhulst, B., Harris, J., Adams, A. M., Benstock, S. E., Tong, C. W.-C., Case, A. J., & Hettema, J. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4720582/v1
Exploring Genomic Approaches in Drug Discovery from Ethnomedicinal Plants
Sharma, D. (2024) · Springer eBooks · doi:10.1007/978-981-97-3405-4_14
Sánchez, F. R. (2022) · theses.fr (ABES) · doi:10.70675/6e26da5bzb271z476cza032zea02c6177bd7
Antisense oligonucleotide drugs for neurological and neuromuscular diseases
Lane, R. M., & Bennett, C. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00039-x
Omics Sciences in Drug Discovery, Safety, and Pharmacokinetics
Tonon, G., Giannese, F., & Lazarević, D. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_131
Li, X., Liu, T., Cammann, D., Cummings, J. L., Xu, L., & Chen, J. (2024) · Research Square · doi:10.21203/rs.3.rs-5339703/v1
Huang, J., Li, Z., & Lin, Y. (2025) · medRxiv · doi:10.1101/2025.01.02.25319933
Levey, D. F., & Gelernter, J. E. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0028
Yang, Z., Qiu, X., Ma, A., Wu, C., Zong, X., Nie, Y., Zhan, S., Yang, H., Zhang, C., Song, H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.162932
Lin, J., Xu, Q., & Zhao, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-02683-0
Huang, P., He, Y., Zhi, N., Yi, W., Guo, C., Jiang, Z., & Zhang, H. (2025) · European Spine Journal · doi:10.1007/s00586-025-09005-6 · Cited by 1
Zanders, E. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-93949-5_5
Zhou, E., Luo, S., Xiao, Y., Liu, B., & Xiao, X. (2025) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1002/wjo2.70038
Yang, Y., Feng, Z., Zhang, Z., Ma, J., Li, J., Luo, W., Liu, F., Ma, N., Murata, M., & He, F. (2025) · Research Square · doi:10.21203/rs.3.rs-6957738/v1
Complex Genetic Control of Autoimmune Disease
Droscher, E., & Bull, K. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00251-9
Chen, R., Siciliano, B., Wang, Q., Xu, C., Wei, Q., Yang, H., Sutcliffe, J. S., Jiang, Y. W., Ji, Y., Liu, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202508519
Genetic Architecture of Host Proteins Involved in SARS-CoV-2
Abdullah, Ibrar, M., & Khan, F. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815322194125010009
A Modification to Two‐Stage Least Squares With Genetic Applications
Fang, L., & Pan, W. (2025) · Statistics in Medicine · doi:10.1002/sim.70308 · Cited by 1
Wang, C., Cai, Y., & Jie, J. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157075
Seto, M., Klinger, H. M., Clifton, M. J., Janve, V. A., Brown, J. A., Birkenbihl, C., Coughlan, G., Townsend, D. L., Wang, T., Properzi, M. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.21.689770
Wang, Y., Sun, Y., Yang, Y., Guan, L., & Han, T. (2025) · All Life · doi:10.1080/26895293.2025.2589222
Zhao, R., Huang, Y., Qu, X., Zhang, J., Tang, D., Xie, Z., Luo, X., Li, Z., & Li, N. (2025) · Analytical Cellular Pathology · doi:10.1155/ancp/3279688
Chen, C., Li, X., Zhang, X., Hu, M., Yang, M., Yuan, Z., Yao, S., Qin, S., Qin, Y., & Xiao, Y. (2025) · Journal of Asthma and Allergy · doi:10.2147/jaa.s550648
Dhall, A., Pyclik, A., Ung, M. H., Etchin, J., Keschner, Y., Ge, H. G., Chakraborty, T., & Lydeard, J. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.15.694499
Colbourne, L. (2024) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-zgob1aq1q
The Impact of High Dietary Glucose on Amyloid-Beta Proteotoxicity in Caenorhabditis elegans
Kerslake, E. A. (2024) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/rc9m-by06
Additional file 1 of Estimating colocalization probability from limited summary statistics
King, E. A., Dunbar, F., Davis, J. W., & Degner, J. F. (2021) · Figshare · doi:10.6084/m9.figshare.14608489
Self-citationMoncla, L.-H. M., Mathieu, S., Sylla, M. S., Bossé, Y., Thériault, S., Arsenault, B. J., & Mathieu, P. (2022) · Figshare · doi:10.6084/m9.figshare.20486764
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644714
Additional file 9 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622570
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644711
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644660
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644657
Gu, X., Dou, M., Su, W., Jiang, Z., Duan, Q., Cao, B., & Chen, Y. (2023) · Figshare · doi:10.6084/m9.figshare.22599622
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644690
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644702
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644651
Breeze, C. E., Haugen, E., Reynolds, A. P., Teschendorff, A. E., van Dongen, J., Lan, Q., Rothman, N., Bourque, G., Dunham, I., Beck, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.18070603
Song, W., Li, Y., Yao, Y., Sun, S., Guan, X., & Wang, B. (2024) · Figshare · doi:10.6084/m9.figshare.26729710
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644675
Montefiori, L. E. (2019) · Knowledge@UChicago (University of Chicago) · doi:10.6082/px8tq-se365
Song, W., Li, Y., Yao, Y., Sun, S., Guan, X., & Wang, B. (2024) · Figshare · doi:10.6084/m9.figshare.26729707
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644684
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644672
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644645
Applicazioni dell’Intelligenza Artificiale ai processi di Ricerca & Sviluppo preclinico del farmaco
Malva, A., Priami, C., Turchetti, G., Pelliccia, A., Dall’Olio, G., & Recchia, G. (2019) · CINECA IRIS Institutial research information system (University of Pisa) · doi:10.32032/tendenze201908.pdf
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644648
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644666
Khan, Z., Jung, M., Crow, M., Mohindra, R., Maiya, V., Kaminker, J. S., Hackos, D. H., Chandler, G. S., McCarthy, M. I., & Bhangale, T. (2023) · Figshare · doi:10.6084/m9.figshare.23558033
Additional file 1 of CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N., Beesley, J. M., Manning, M., Shi, W., Perlaza-Jiménez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D. M., Civitarese, A., McCue, K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22622546
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644663
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644654
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644678
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644693
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644687
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644708
Inflammatory pathways as drug targets for autoimmune disease
Konieczny, M. (2025) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.35281
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644669
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644699
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644696
Rajasundaram, S., Zebardast, N., Mehta, P. A., Khawaja, A. P., Warwick, A., Duchinski, K., Burgess, S., Gill, D., Segrè, A. V., & Wiggs, J. L. (2024) · Figshare · doi:10.6084/m9.figshare.26644681
Stanzick, K. J., Stark, K. J., Gorski, M., Schödel, J., Krüger, R., Kronenberg, F., Warth, R., Heid, I. M., & Winkler, T. W. (2024) · Figshare · doi:10.6084/m9.figshare.26618800
Breeze, C. E., Haugen, E., Reynolds, A. P., Teschendorff, A. E., van Dongen, J., Lan, Q., Rothman, N., Bourque, G., Dunham, I., Beck, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.18070600
Perée, H. (2025) · ORBi (University of Liège)
Leveraging genetic epidemiology methods for drug target discovery
Liang, K. Y. H. (2025) · eScholarship@McGill (McGill) · doi:10.82308/23749
Lu, M., Chu, Y., Zhu, Z., Zhou, H., Zhu, D., Chen, S., Bu, C., Qian, Q., Gao, C., Jiang, M., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.01.014
Butterworth, A. S., Gaziano, L., & Angelantonio, E. D. (2026) · Apollo (University of Cambridge)
“Yet the Problem Remains”: Why Genetic Determinism Still Haunts Biomedical Research
Donohue, C., & Myles, I. A. (2026) · Bioethics · doi:10.1111/bioe.70102
Zhang, G., Xia, J., Zhou, Y., Qian, J., Yin, D., & Lv, W. (2026) · Discover Oncology · doi:10.1007/s12672-026-04672-3
Geng, Y.-N., Dong, X., Liu, Y., & Dong, Y. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.111849
Duncan, E. L., & Brown, M. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00040-2
Gene discoveries and novel therapies in monogenic low and high bone mass disorders
Hendrickx, G., Padidela, R., & Mäkitie, O. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00022-0
Yoshiji, S. (2024) · eScholarship@McGill (McGill) · doi:10.82308/23011
Valenti, L. V. C., & Malvestiti, F. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.03.031
Metadata
- Authors
- King, E. A., Davis, J. W., & Degner, J. F.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- King, Emily A.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-12
- Volume
- 15
- Issue
- 12
- Pages
- e1008489
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC6907751
- OpenAlex
- W2995245946
- Cited by
- 649
- References
- 40
- Citations by year
- 2026: 71 · 2025: 97 · 2024: 132 · 2023: 118 · 2022: 92 · 2021: 85 · 2020: 47 · 2019: 6
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- drug approval, therapeutic target, genetic evidence, drug development pipeline, new chemical entities, monogenic disorders, genome-wide association study, coding variants, drug development investment
- MeSH terms
- Pharmacogenomic Variants, Humans, Phenotype, Models, Statistical, Drug Approval, Genetic Predisposition to Disease, Genomics, Databases, Genetic, Quantitative Trait Loci, Genome-Wide Association Study, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.